INTRODUCTION
============

Schizophrenia is a severe and chronic psychiatric disorder consisting of a heterogeneous group of symptoms and cognitive impairments. On the basis of the convergent evidence from the fields of epidemiology, imaging and post-mortem analysis, the neurodevelopmental hypothesis and the dopamine (DA) hypothesis have become two major theories of schizophrenia. The developmental hypothesis proposes that genetic or environmental factors during critical early periods of brain development adversely impact on adult mental health ([@B109]; [@B154]). The DA hypothesis proposes that DA dysfunction is central to the pathogenesis of schizophrenia ([@B27]; [@B133]; [@B11]; [@B42]; [@B94]; [@B2]). Recently, these two theories were revised and integrated through the substantial evidence that all the developmental risk factors which increase the risk of schizophrenia, appear to share a common endpoint or "final common pathway" of DA dysfunction ([@B47]; [@B111]; [@B72]).

Clinical studies provide strong evidence of DA dysfunction in patients. Patients with schizophrenia show increased amphetamine-induced DA release in the striatum ([@B18]; [@B92]; [@B93]; [@B3]) and have altered presynaptic DA function, specifically increased DA synthesis capacity ([@B74]; [@B61]). These factors are highly associated with psychosis ([@B71]) and are generally not evident in stable schizophrenia patients that are not acutely experiencing a psychotic episode ([@B93]; [@B134]). However, increased presynaptic DA function can also be observed during the prodromal phase of the disease ([@B76]) and in ultra-high risk subjects who then go on to develop psychosis ([@B75]). Thus, it would appear that alterations in presynaptic DA function precede the onset of frank psychosis, suggesting that intervention prior to symptom onset may even offer the potential for preventing disease onset.

Substantial evidence from animal models indicates that fetal or perinatal factors can result in long-term alterations in dopaminergic function. For example, animal models designed to examine obstetric complications, such as fetal or neonatal hypoxia, resulted in increased DA-mediated behavioral responses, increased DA release and elevated basal DA in subcortical regions ([@B16]; [@B15]; [@B17]; [@B44]). Rodent models with prenatal exposure to virus-like agents (e.g., the synthetic double-stranded RNA, Poly I:C) that explore the neurobiological correlates of maternal infection ([@B107]) also exhibit increased levels of DA and DA metabolites and enhanced striatal DA turnover ([@B120]; [@B158]). In addition, heuristic evidence that early dopaminergic alterations can lead to impaired cognition and behavior later in life has also been described. For example, [@B81] have shown persistent deficits in cognition and altered DA function in a mouse model that transiently overexpresses DA 2 receptors in the striatum during development. Thus, abnormal DA signaling early in development would appear to produce long lasting impairments in brain function.

Evidence continues to mount from both epidemiological and pre-clinical studies to indicate that developmental vitamin D (DVD) deficiency may be also an important developmental risk factor for schizophrenia. Over the past decade, our studies on the DVD-deficient rat model firmly established that DVD deficiency affects brain cell proliferation, differentiation, and gross brain structure, it also produces long-lasting cellular changes and alterations in behavior in the adult offspring. In particular, the DVD-deficient adult offspring display enhanced DA-related behavioral responses and alterations in DA signaling. Understanding the mechanism of action linking DVD deficiency with altered DA signaling could provide clues to shared pathways underpinning the pathogenesis of schizophrenia.

In this article, we integrate findings derived from the DVD-deficient rat model and schizophrenia to propose that developmental DA dysfunction may be a core factor in the susceptibility and/or development of schizophrenia (**Box [1](#BX1){ref-type="boxed-text"}**). We begin with a concise summary of the epidemiological clues that suggest altered prenatal/perinatal vitamin D levels increase the risk of developing schizophrenia. Subsequently we introduce the DVD-deficient rat, discussing evidence from both early development and in adult offspring suggesting alterations in DA development and function. Furthermore, the multiple signaling pathways that may lead to such DA abnormalities in the DVD-deficient rat are also discussed. The final section reviews how DVD deficiency could lead to long-lasting neuroanatomical, neurochemical, and behavioral changes that are relevant to schizophrenia, and in particular, DA dysfunction.

###### Box 1. Salient points.

• *Schizophrenia*

Neurodevelopmental disorder associated with altered dopamine function both prior to and during disease onset

• *Developmental vitamin D (DVD) deficiency*

Associated with increased susceptibility to schizophrenia

• *DVD rat model*

DVD-deficiency in the rat leads to a pattern of altered developmental and adult dopaminergic function

• *Vitamin D and dopamine*

Early vitamin D signaling is intrinsically linked with the developing dopamine system

• *Animal models of schizophrenia*

Multiple animal models of schizophrenia show alterations in dopamine development prior to post-adolescent alterations in behavior

• *Dopamine and schizophrenia*

Although focus remains tied to dopamine as a common endpoint in schizophrenia, understanding common dopaminergic origins may be

THE EPIDEMIOLOGY OF VITAMIN D AND SCHIZOPHRENIA
===============================================

Numerous pieces of epidemiological evidence implicate low levels of maternal vitamin D as a potential risk factor for schizophrenia. Firstly, one of the most replicated findings is that people born in the winter and spring months of the year have an increased risk of developing schizophrenia later in life ([@B143]; [@B102]; [@B41]), and this risk is larger at high latitudes that feature greater seasonal fluctuations ([@B41]). Secondly, people born in urban areas in comparison with those born in rural environments have an increased risk of developing schizophrenia ([@B142]; [@B102]). Finally, the incidence of schizophrenia is significantly higher in the second generation of dark-skinned migrants to cold countries compared to native-born individuals ([@B26]). Moreover, first generation migrants who arrive as babies or infants also have an increased risk of schizophrenia ([@B146]). This risk decreases with the increasing age of the migrant suggesting early life environmental conditions are critical. Given that vitamin D deficiency is common (1) during winter and spring, (2) at high latitudes ([@B69]), (3) in urban environments ([@B103]) and (4) in dark skinned individuals ([@B33]; [@B69]), these ecological data led to the hypothesis that low maternal vitamin D could be a modified risk factor for schizophrenia.

The direct analytical evidence in support of this hypothesis has also now been demonstrated. Schizophrenia has been shown to be ameliorated by vitamin D supplementation in the 1 year of life ([@B104]). Most recently, and most importantly, a Danish population-based case-control study (423 cases and 423 control) that directly assessed vitamin D levels in blood spots from new born infants provided solid evidence showing that low prenatal vitamin D levels are associated with an increased risk of schizophrenia ([@B105]). Taken together, these data support the hypothesis that an absence of vitamin D during development may lead to an increased risk of schizophrenia. To establish the biological plausibility of whether DVD deficiency could be related to schizophrenia, our group established a DVD-deficient rat model which has shown that low prenatal vitamin D adversely affects brain development and adult behavior, especially DA development and DA-related behaviors.

THE DVD-DEFICIENT RAT MODEL OF SCHIZOPHRENIA
============================================

DVD-deficient offspring are produced by feeding female Sprague-Dawley rats a diet that lacks vitamin D but contains normal calcium and phosphorous. Rats are maintained on this diet for 6 weeks, after which and prior to mating, serum vitamin D~3~ depletion is confirmed by measuring the stable vitamin D metabolite 25 hydroxy-vitamin D (25(OH)D~3~) as \<0.34 ng/ml ([@B52]). Vitamin D deficient dams are maintained on the vitamin D depleted diet until the birth of pups. Control animals are kept under identical conditions but are supplied with standard rat chow containing vitamin D~3~. All dams (both control and depleted) are kept under standard housing conditions (control rat chow) after giving birth. Although vitamin D~3-~depleted dams and offspring remain normocalcemic, increased parathyroid hormone levels have been observed in both the dams and pups ([@B40]; [@B23]). In this model the exposure to vitamin D~3~ depletion is only transient as all dams are returned to a normal vitamin D containing diet ate birth. This is sufficient to replete DVD-deficient offspring to normal vitamin D~3~levels by two weeks of age. Importantly, calcium levels in vitamin D deficient dams and DVD-deficient pups are not altered by this protocol ([@B56]; [@B115]). The acute effects of DVD deficiency including abnormal brain development, changes in gross brain structure and altered neurochemistry in addition to persistent alterations in behavior will be discussed in the following sections.

BRAIN DEVELOPMENT IN THE DVD-DEFICIENT RAT
==========================================

The idea that DA dysfunction represents the "final common pathway" in schizophrenia ([@B47]; [@B111]; [@B72]) is supported by strong evidence of abnormal DA signaling in the *adult patient*, particularly at the presynaptic level ([@B74]; [@B61]). However, we know little about the up-stream *developmental alterations* in DA physiology that may underpin these effects. For example, early life risk factors associated with schizophrenia may change the way DA systems develop. Thus, increases in presynaptic DA function in individuals who progress to clinical schizophrenia may result from abnormalities in the early ontogeny of DA systems. Animal models, such as the DVD-deficient rat, allow for more thorough investigations into early developing neurotransmitter systems and early developmental alterations that lead to behavioral and neurochemical abnormalities in the adult.

EARLY DOPAMINERGIC ABNORMALITIES
--------------------------------

Embryonic DA neuron development is a dynamic process with multiple factors responsible for normal function. In the rat, differentiation of monoamine cells in the substantia nigra (located in the midbrain) begins as early as embryonic day (E) 11 with the peak period of DA neuron birth occurring at E12([@B95]; [@B62]). Subsequent innervation of the striatum in the basal ganglia from midbrain monoamine neurons occurs from E14-17([@B148]). DVD deficiency has been shown to alter the gene expression of key DA specification factors (i.e., factors involved in the phenotypic development of DA neurons) at both of these crucial time-points in DA development. At E12, coinciding with monoamine cell differentiation, expression of Nurr1 and p57Kip2 were decreased in DVD-deficient rats ([@B40]). Tyrosine hydroxylase (TH; the rate limiting enzyme in DA synthesis and a reliable marker of DA neurons) also appeared to be reduced in DVD-deficient embryos at this same time point. Nurr1 expression was also decreased at E15. This represents a period when dopaminergic innervation of the striatum begins to occur. Nurr1 (also known as NR4A2), an orphan nuclear receptor, is an essential factor in DA neuron development and maturation ([@B152]) and p75Kip2 cooperates with Nurr1 during DA cell development ([@B80]). Nurr1-deficient mice show complete DA neuron agenesis ([@B161]) and Nurr1 has been shown to directly activate the TH promoter gene in cell cultures ([@B131]; [@B77]; [@B87]). Therefore, decreased Nurr1 expression coupled with a trend for reduced TH expression strongly suggests decreased or delayed DA cell differentiation in DVD-deficient rats.

These alterations in DA specification factors during development in the DVD-deficient rat compliment alterations in DA turnover identified at birth. Under normal conditions, the majority of DA metabolism is through intra-neural oxidative deamination via monoamine oxidase (MAO) to produce dihydroxyphenylacetic acid (DOPAC). This is followed by a subsequent extra-neural *O*-methylation via catechol-*O*-methyl transferase (COMT) to form homovanillic acid (HVA; [@B155]). DVD-deficient pups show a 45% reduction in brain COMT levels at birth ([@B83]). Moreover, this reduction in COMT is associated with an increased ratio of DOPAC to HVA, suggesting altered DA turnover. COMT remains an interesting target for schizophrenia research with less efficient isoforms increasing the risk of schizophrenia when coupled with adolescent marijuana use ([@B72]). Thus, DVD deficiency directly impacts on factors that are essential in early DA neuron development and embryonic DA turnover.

GROSS BRAIN ANATOMY, MITOSIS AND APOPTOSIS
------------------------------------------

The initial absence of vitamin D also affects other, more general, aspects of brain development that do not directly relate to DA neurons. For example, gross brain architecture is different in that DVD-deficient pups have cerebral hemispheres that are longer but not wider than control pups ([@B53]). Furthermore, when corrections were made for the altered shape of these brains, the lateral ventricles were larger but the neocortex thinner than in control pups. Enlarged lateral ventricles have been observed in patients with schizophrenia and represent one of the more replicated neuroanatomical findings in schizophrenia ([@B31]; [@B112]; [@B121]). These brain anatomical changes were also associated with altered rates of cellular proliferation.

Vitamin D is known to be involved in the modulation of cellular proliferation and apoptosis in many tissues ([@B13]; [@B49]). In the developing brain, levels of vitamin D receptor (VDR) expression coincide with increasing levels of apoptosis and decreasing levels of mitosis ([@B20]) suggesting similar actions to that seen in peripheral tissue. Conversely, the absence of vitamin D in the embryonic brain results in increased levels of mitosis and decreased levels of apoptosis ([@B53]; [@B88]). DVD deficiency also altered gene expression profiles regulating mitosis and apoptosis in the brain ([@B88]). Furthermore, neurosphere cultures derived from DVD-deficient rat pups result in a greater number of neurospheres than cultures from control rat pups ([@B39]), also suggesting increased cellular proliferation. Thus at both the cellular and transcriptional levels, vitamin D appears fundamentally involved in the rate of proliferation and cell death in the brain. These early alterations in both DA signaling, brain structure and proliferation in DVD-deficient offspring appear to produce associated abnormal neurochemistry and behavior in adulthood.

ALTERATIONS IN ADULT DVD-DEFICIENT OFFSPRING
============================================

DOPAMINE-BASED ALTERATIONS
--------------------------

Subcortical DA function is an essential factor with regard to novelty-induced behavioral activation ([@B70]) and both novelty and stress (i.e., handling etc.) result in increased DA release in the prefrontal cortex (PFC; [@B57]). Moreover, enhanced responsiveness to novelty is associated with an increased response to agents that enhance synaptic DA levels ([@B29]). Adult DVD-deficient rats show enhanced novelty-induced locomotion on a range of tasks including the hole board and elevated plus maze ([@B21]; [@B82]). Interestingly, this enhanced response can be attenuated in DVD-deficient rats with handling procedures and injections ([@B22]; [@B82]).

Amphetamine has been shown to induce psychotic-like phenotypes in non-psychotic individuals and schizophrenia patients show enhanced DA release and positive symptoms relative to healthy individuals after exposure to low doses ([@B78]; [@B98]; [@B93]). Amphetamine-induced behaviors in rodents are therefore considered a model of the psychotic symptoms seen in schizophrenia. Amphetamine induces DA release in the brain primarily due to actions at the DA transporter (DAT; [@B138]; [@B156]; [@B79]). Female DVD-deficient rats show an increased sensitivity to amphetamine-induced locomotion as adults but not juveniles ([@B84]). Although male DVD-deficient rats do not show an enhanced response after an acute dose of amphetamine, a similar sensitivity to amphetamine appears to occur after multiple doses ([@B84]). Adult female DVD-deficient rats also have increased levels of DAT in the caudate putamen (CPu) and increased affinity for DAT ligands in the nucleus accumbens (Acb; [@B84]) suggesting alterations in DAT function may mediate the enhanced response to amphetamine.

DVD-deficient rats also show increased sensitivity to the antipsychotic haloperidol ([@B82]). Haloperidol is a typical antipsychotic used to treat the positive symptoms of schizophrenia and its antipsychotic potency is directly related to the blockade of DA 2 receptors ([@B133]; [@B36]). DA 2 receptors however, do not appear to be altered in DVD-deficient rats ([@B84]) indicating the behavioral response to haloperidol in DVD-deficient rats is more complex than a simple change in receptor density. Overexpression of DA 2 receptors in schizophrenia appears to have only a small effect size ([@B91]; [@B132]) and as such is not necessarily a key feature of the disease even though all antipsychotic drugs target these receptors. Thus, DVD deficiency induces persistent post-adolescent sensitivity to the behavioral effects of dopaminergic drugs that appears to mirror the post-adolescent onset of frank psychotic symptoms in schizophrenia patients and these sensitivities can be attenuated with the use of antipsychotic drugs.

Aspects of learning and memory are also affected in DVD-deficient rats. Latent inhibition refers to a learning phenomenon describing how it takes longer to associate relevance to a familiar stimulus than a novel stimulus. DVD-deficient rats have impaired latent inhibition ([@B14]) suggesting a deficit in the ability to attend selectively to relevant stimuli. Acutely psychotic patients also show impairments in latent inhibition ([@B64]; [@B100]) and DA agonists have been shown to decrease latent inhibition in healthy adult males ([@B140]). Moreover, DVD-deficient rats show increased impulsivity and a lack of inhibitory control when assessed on the 5-choice continuous performance task ([@B144]). The increased impulsivity in DVD-deficient rats can also be attenuated with the atypical antipsychotic, clozapine. Impulsivity in healthy humans has been associated with the availability of the DAT ([@B35]) and in rats; DA receptors in the medial PFC also appear to be critical ([@B124]). Thus multiple DA-based behavioral alterations are present in the adult DVD-deficient rat. However, other neurotransmitter systems, closely linked to the DA system, also appear to be affected in DVD-deficient rats.

ALTERNATIVE NEUROTRANSMITTER SYSTEM ALTERATIONS
-----------------------------------------------

The use of N-methyl-[D]{.smallcaps}-aspartic acid (NMDA) receptor antagonists such as PCP, ketamine and MK-801 in animal models has become more widespread because the symptoms elicited in healthy people are more similar to those seen in people with schizophrenia than those observed after amphetamine ([@B89]; [@B90]). As a result, NMDA receptor hypofunction models of schizophrenia have been proposed and are also widely studied ([@B116]). DVD-deficient rats show a consistently enhanced locomotor response to MK-801([@B82]; [@B115]; [@B85]). Importantly, this behavioral sensitivity is heavily dependent on the timing of vitamin D deficiency. Vitamin D deficiency in the later portion of gestation is required to elicit this behavioral sensitivity whereas vitamin D deficiency during the early portion of gestation has no impact ([@B115]). Coincidently, the later portion of gestation includes active DA neuron migration, differentiation and innervation in the embryonic brain. Although it is fairly clear that DA release is not required for the effects of MK-801 on locomotion ([@B28]), DA receptor antagonists have been shown to attenuate MK-801-induced behavior ([@B37]; [@B157]; [@B9]; [@B82]). Consistent with this, the enhanced locomotor response to MK-801 in DVD-deficient rats is selectively blocked by pretreatment with the DA 2 receptor antagonist haloperidol, at a dose that does not significantly attenuate MK-801-induced locomotion in control rats ([@B82]). This suggests that abnormal DA signaling remains a component of the enhanced response to MK-801 consistently observed in DVD-deficient rats.

*In Summary*, DVD deficiency results in multiple outcomes in the adult animal that suggest neurotransmission and neuron integrity may be compromised. In addition, there is strong evidence that the altered response to psychomimetic drugs in adult DVD-deficient rats appears closely linked to DA function. The mechanism for how the developmental absence of vitamin D may influence DA signaling in the adult remains unknown. However given the multiple pieces of evidence indicating early alterations in the ontogeny of DA systems in this model we suspect this may hold the key.

LINKING DOPAMINE ABNORMALITIES TO DVD DEFICIENCY
================================================

EARLY VITAMIN D SIGNALING AND DOPAMINE
--------------------------------------

Vitamin D is a nuclear steroid. Its signaling is via a single nuclear receptor called the VDR which is expressed widely throughout the human ([@B139]; [@B160]; [@B55]) and rat brain ([@B34]; [@B60]; [@B128]). The VDR shares structural characteristics with other nuclear steroid receptors ([@B101]). After ligand binding the VDR forms a heterodimer with the retinoid X receptor (RXR). This complex binds to vitamin D response elements (VDRE) in the promoters of a number of genes; to regulate their transcription ([@B30]). Expression of the VDR begins early in development ([@B60]; [@B145]; [@B51]; [@B20]; [@B38]) and increasing levels of VDR coincide with increasing levels of apoptosis and decreasing levels of mitosis ([@B60]; [@B145]; [@B51]; [@B20]). However, it is the coincident expression of the VDR within developing DA neurons ([@B38]) and projections in the brain that suggest an important role for vitamin D in the developing DA system.

### Effects of Vitamin D on dopamine differentiation and innervation

Expression of the VDR can be found as early as E12 in the neuroepithelium ([@B145]) coinciding with the peak differentiation of monoamine cells in the substantia nigra; the primary source of midbrain dopaminergic projections to the basal ganglia ([@B95]; [@B62]). As dividing mesencephalic DA progenitor cells stop proliferating, they immediately begin to express specification factors \[initially Nurr1 ([@B80]) with p57Kip2 expressed soon after ([@B151])\] that help to establish the neurotransmitter phenotype of these cells. DVD-deficient E12 embryos show decreased gene expression of Nurr1, p57Kip2 and TH ([@B40]) suggesting altered vitamin D signaling affects early monoamine cell development, perhaps even prior to E12. Not surprisingly, all three of these factors are linked and it would appear that Nurr1 is the upstream effector that results in altered p57Kip2 and TH levels. For example, Nurr1 has been shown to activate the expression of p57kip2 which then cooperates with Nurr1 in the maintenance of DA neurons ([@B80]). Moreover, Nurr1 has been shown to regulate important proteins in DA synthesis and function including TH, vesicular monoamine transporter 2 (VMAT2) and DAT ([@B135]). Thus a decrease in Nurr1 expression would be expected to result in decreased p57Kip2 and TH as found in the DVD-deficient embryo.

Monoaminergic striatal innervation occurs from E14-17 ([@B148]) with functional release observed at E18 ([@B114]). Consistent with the premise that vitamin D plays a role in dopaminergic cell development, VDR expression in the differentiating field of the midbrain and basal ganglia can be observed by E15 ([@B145]). Furthermore, DVD-deficient embryos show decreased expression of Nurr1 at E15 ([@B40]). Thus, the appearance of the nuclear expression of the VDR in the mesencephalon at the peak period of DA neuron differentiation raises the possibility that the absence of vitamin D at this point may lead to changes consistent with the absence of this ligand. Namely, increased rates of DA neuron proliferation and delayed differentiation. This is consistent with the reduction in the expression of post-mitotic specification factors such as Nurr1. Interestingly, although Nurr1 gene expression in the mesencephalon peaks from E13 to E15 ([@B147]) the levels of Nurr1 in the developing rat cortex show a different temporal window of expression with peak protein levels occurring later at P1 ([@B97]). Whether the levels of cortical Nurr1 are decreased or delayed as observed in the mesencephalon of DVD-deficient rats is currently unknown.

How the absence (or presence) of vitamin D could alter Nurr1 levels remains unknown. However, retinoid function and specifically the interactions of retinoid receptors and Nurr1 have led researchers to suggest that retinoid signaling may be one link between the genetic and environmental susceptibility to schizophrenia ([@B122]). Both Nurr1 and the VDR form heterodimers with the RXR ([@B101]; [@B125]; [@B1]). Indeed, signaling through the RXR-Nurr1 heterodimer is involved in the neuroprotective actions of Nurr1 in DA neurons ([@B150]). However, in rat neural precursor cells the RXR-Nurr1 heterodimer has been shown to *reduce* Nurr1 activity in DA neuron generation and *reduce* TH promoter activity ([@B159]). It is important to note that levels of the VDR are unaltered in DVD-deficient pups ([@B53]) allowing for ligand-independent actions. The interactions between, and functions of, the VDR and RXR appear to be extremely dependent on the presence of vitamin D. For example, the VDR-RXR heterodimer with no ligand acts as a weak transcriptional repressor ([@B141]). Furthermore, when no ligand is present the RXR increases the nuclear accumulation of VDR by slowing nuclear export whereas, when bound to vitamin D, the VDR regulates the import of the RXR into the nucleus ([@B127]). Thus the non-ligand bound VDR may lead to decreased levels of cytosolic VDR and reduced competition for RXR compared with Nurr1. This may lead to an increase in the inhibitory functions of the RXR-Nurr1 heterodimer on DA neuron generation ([@B159]). Decreased DA neuron generation would subsequently lead to reduced levels of Nurr1 and TH as found in DVD-deficient embryos. The presence and interaction of the VDR (minus ligand) on the availability or function of the RXR-Nurr1 heterodimer is unknown but this remains an intriguing target.

In addition, recent work also suggests that Nurr1 expression induces the expression of the glial derived neurotrophic factor (GDNF) receptor, Ret, in adult nigral DA neurons ([@B45]). The decreased Nurr1 levels may therefore decrease GDNF signaling in DVD-deficient embryos. Moreover, evidence continues to accumulate indicating vitamin D positively regulates GDNF levels in the developing mesencephalon ([@B119]). GDNF is an important factor involved in DA neuron development, survival and function ([@B99]; [@B32]; [@B86]). Thus, the combined local expression these three factors (VDR, RXR, and Nurr1) in addition to their cooperative signaling capabilities may be causal for the downstream effects of DVD-deficiency on DA neuron development.

### Effects of Vitamin D on postnatal dopamine events

Developing DA neurons undergo two postnatal phases of natural cell death ([@B117]); the first peak is around postnatal day (P) 2 and the second peak occurs around P14. The combination of these two phases of cell death determines the number of DA cells within the adult brain. There are various regulatory factors involved in this process. For example, the first of these stages is heavily regulated by GDNF levels ([@B118]) and interactions with striatal targets ([@B19]). The second stage is less well understood but the dependence on striatal targets appears to remain ([@B19]). These processes establish DA neuron number and functional connectivity in the juvenile animal. Vitamin D has been shown to increase GDNF synthesis in the brain ([@B153]). Given the importance of GDNF in the postnatal programmed cell death of DA neurons in addition to its roles in DA neuron development, survival and function ([@B99]; [@B32]; [@B86]); this represents a potential factor that could permanently alter key dopaminergic regions that contribute to adult behavior. We assume the levels of Nurr1 in DVD-deficient rats would have returned to control levels by this stage given the trend toward this in embryonic development ([@B40]). However, any consequence of earlier Nurr1 signaling deficits on the expression of the GDNF receptor, Ret, may persevere. Subsequently, this may lead to reductions in GDNF signaling during these crucial phases of DA cell death in DVD-deficient rats.

These DA cell death events are also dependent on the functional interaction of DA neurons and their striatal targets ([@B19]). Therefore, compromised neuronal signaling after DVD deficiency could potentially impact the survival of DA neurons. For example, silencing the VDR in cortical cultures from E16 embryos disrupts L-type voltage-sensitive calcium channels which are involved in calcium homeostasis and neuronal integrity ([@B63]). Furthermore, DVD-deficient pups also show altered DA turnover as a result of decreased levels of COMT ([@B83]). Both of these vitamin D-induced alterations could potentially lead to altered signaling in DA neurons. Thus altered DA signaling at birth suggests that the early postnatal period may represent an early developmental window whereby permanent alterations in DA function may lead to altered adult behavior.

AN ALTERED DEVELOPMENTAL TRAJECTORY
-----------------------------------

### Schizophrenia

One key facet of schizophrenia is the post-adolescent onset of "psychosis" or psychotic symptoms ([@B46]). The wealth of epidemiological evidence for a neurodevelopmental pathogenesis as described throughout this review needs to be considered in the light of the post-adolescent onset of disease ([@B10]). The brain undergoes a high level of reorganization throughout adolescence ([@B137]; [@B7]; [@B4]). Thus, the normal processes involved in brain maturation may be compromised such that the refinement of projections and signaling pathways uncovers or reveals an underlying dysfunction, such as altered genetic architecture ([@B96]) or subtle changes in neurochemical function ([@B73]; [@B76]).

The period of adolescent maturation is of particular importance to the clinical onset of psychotic disorders such as schizophrenia. For example, phencyclidine and ketamine (i.e., NMDA receptor antagonists) fail to produce hallucinations in prepubertal children, however they routinely do in adults ([@B68]). Thus the underlying connectivity/neurotransmission required for these drugs to elicit psychosis analogous to that seen in schizophrenia may not be functional until after adolescence. Obviously the presence of early onset schizophrenia suggests that these same processes *can* be present prior to adolescence but the fact remains that subtle alterations in cytoarchitecture, neurotransmission or brain connectivity may not yield a psychotic phenotype until these maturational processes are established. Importantly, the prodromal phase of schizophrenia that overlaps with this period of maturation is now being linked to dopaminergic abnormalities. For example, individuals at ultra-high risk of developing schizophrenia show increased striatal DA synthesis ([@B73], [@B76]). There is also both behavioral and structural evidence that brain development is altered in people prior to disease onset. For example, behavioral abnormalities, IQ and social deficits have been described in children who later develop the disease ([@B12]; [@B48]; [@B50]; [@B110]; [@B24], [@B25]). Moreover, at the onset of psychosis there are already changes in the gross anatomy of patients' brains. For example, the lateral ventricles are increased in size ([@B31]; [@B112]; [@B121]) and the cortex of schizophrenia patients frequently has decreased white and gray matter volume ([@B66]; [@B123]; [@B31]; [@B112]; [@B121]). More recently two studies have shown that decreases in the gray matter volume of the parietal cortex and hippocampus precede the onset of psychosis in prodromal patients ([@B106]; [@B43]). Thus, there are a number of changes reflecting altered brain development and these appear to be present well before the onset of the symptoms required for clinical diagnosis.

Although cases of early onset schizophrenia suggest these adolescent maturational processes are not "key" per se, they still seem to play a significant role. For example, the decreases in cortical thickness found in early onset schizophrenia become more localized and more akin to those seen in adult onset schizophrenia when these patients reach adulthood ([@B65]) suggesting a role for adolescent maturation even in those with early onset schizophrenia. Furthermore, these examples also support a hierarchy of susceptibility in that highly susceptible individuals may be compromised earlier in life whereas others may require further extended environmental or developmental stressors to elicit frank symptoms. The fact that the enlarged lateral ventricles in DVD-deficient rats only persist to adulthood when the period of vitamin D deficiency is extended to weaning ([@B53]; [@B58]) supports a titratable approach to brain susceptibility. In addition, it also suggests that further study on the temporal window of vitamin D deficiency would be extremely informative.

### Rodent Analogs

There are notable similarities between adolescent/sexual maturation in rodents and humans. For example, the course of sexual maturation in rodents is preceded by the overproduction of synapses and accompanied by their subsequent elimination ([@B8]). These dynamic changes in receptor density are thought to reflect the focussing and strengthening of synaptic connections required for adult life. This also occurs in humans with an estimated loss of almost one-half of the average number of synapses per cortical neuron over the adolescent period ([@B129]). This period therefore represents a window whereby external influences prior to, rather than after, can differentially impact on adult brain function in both rodents and humans ([@B137]; [@B7]; [@B4]). Of particular interest to both DVD deficiency and schizophrenia are the dynamic changes observed in the DA system over this period. For example, in the rat the density of both D1 and D2 receptors increase in the striatum prior to puberty, followed by their decline during puberty ([@B8]). However, it is important to note that the development and maturation of the DA system is a dynamic process with behavioral and neurochemical responses continuing to change in rats for years after birth ([@B67]; [@B130]).

Akin to drug sensitivities and the psychotic symptoms observed in schizophrenia, postpubertal psychomotor sensitivities to drugs such as amphetamine and MK-801 have been found in developmental animal models after DVD deficiency ([@B84]), gestational disruptions in neurogenesis ([@B59]), neonatal ventral hippocampal lesions ([@B5]) and prenatal Poly I:C administration ([@B108]). Taken together these suggest a myriad of interventions can result in psychotic-like drug sensitivities that become observable after adolescence. Perhaps the most important aspect of these models is that they do not include any additional "stressor" during the adolescent period and are the sole results of early life interventions that alter normal brain development. Early intervention with antipsychotic treatment has already been shown to attenuate structural and behavioral abnormalities after prenatal Poly I:C administration ([@B126]) emphasizing that the developmental cascade prior to adolescence is critical to the "schizophrenia phenotype." Furthermore, these models also provide the ability to investigate developmental abnormalities induced by a range of interventions and identify the convergent etiological pathways that result in similar adult behavioral phenotypes.

DOPAMINE: A COMMON ENDPOINT OR A COMMON BEGINNING
=================================================

The premise that no single genetic vulnerability or molecular factor "causes" schizophrenia is well accepted amongst the research community and is confirmed by both the heterogeneity of the symptom profile and the lack of a diagnostic marker. A common endpoint, that includes aspects of DA dysfunction ([@B47]; [@B111]; [@B72]), remains highly supported by the clinical evidence and allows for a specific outcome to investigate the etiology of the disease. However, we postulate that a common DA endpoint may arise precisely because it is central to the developmental pathology (**Figure [1](#F1){ref-type="fig"}**). The dopaminergic system is one of the most organized neurotransmitter systems in the brain and is fundamental for a range of functions involved in cognition, motivation and reward ([@B136]; [@B6]; [@B113]). Furthermore, alterations in DA signaling have a range of cascading effects on other neurotransmitter systems such as glutamate (e.g., NMDA) and GABA. Therefore, even small alterations in DA function or organization have the potential to lead to complex cognitive outcomes when coupled with other general and variable insults such as altered genetic architecture, drug use, stress or adolescent maturation. In addition, these secondary stressors may individually produce differing phenotypes and thus heterogeneity in symptom profile.

![**Temporal profile of developing schizophrenia symptoms.** Early alterations in dopamine development due to genetic, environmental or a combination of both lead to abnormalities in dopamine function (positive symptoms) and subsequent alterations in other neurotransmitter systems (negative symptoms). During adolescence and the prodromal phase of the disease clear changes in dopamine function can be observed. Frank psychosis and disease onset are directly related to dopaminergic function and can be effectively treated. The lack of effect of antipsychotic treatment on persisting negative symptoms suggest they are not directly related to dopamine function. Rather, they represent the downstream consequence of early dopamine dysfunction or the extraneous effects of specific genetic and environmental risk factors on other neurotransmitter systems such as glutamate and GABA. These non-specific actions, outside of the core schizophrenia etiology, result in a large heterogeneous profile of negative symptoms in patients.](fncel-07-00111-g001){#F1}

Our work the in DVD-deficient rat model suggests that the developmental absence of this ligand produces discrete alterations in how DA systems develop. Alterations in DA specification factors ([@B40]) and DA metabolism ([@B83]) induced by DVD deficiency could have lasting influences on the DA signaling. Additionally, these animals show behavioral sensitivities to psychomimetic drugs at adulthood ([@B82], [@B84], [@B85]; [@B115]) which model at least the positive symptoms of schizophrenia ([@B92]; [@B90]). Moreover, another developmental model, that utilizes PolyI:C to mimic prenatal infection, also shows alterations in Nurr 1, and similar behavioral sensitivities to these psychomimetic drugs in adulthood ([@B108]; [@B149]). Taken together this suggests that vastly differing developmental insults can cause similar phenotypes and perhaps even converge on common early mechanisms ([@B54]). Thus a network of small communication errors, perhaps via the interaction of a variety of key receptors (RXR, VDR, Nurr1, Ret) result in an altered developmental landscape. This may lead to an altered number of DA neurons after perinatal cell death events or altered DA functionality/connectivity.

The data amassed in the DVD-deficient rat suggest that subtle developmental alterations in DA function can lead to an altered adult behavioral phenotype. Moreover, utilizing differing developmental insults, animal models have demonstrated similar developmental dopaminergic abnormalities and adult behavioral phenotypes. Therefore, schizophrenia may be a disorder occurring via genetic or environmental factors that features a common early disruption in DA development. The emerging data suggesting that altered DA function precedes the onset of psychosis further suggests that dopaminergic abnormalities are not a byproduct of psychosis but rather a latent signal of altered DA development. Thus, altered dopaminergic function in schizophrenia may represent a potential biological marker and even a target for intervention.

CONCLUSION
==========

Schizophrenia is an extremely complex disorder. We are not suggesting that future therapeutic interventions be limited to a simple "fix DA early and fix schizophrenia" interpretation. However, observations in the DVD-deficient rat, alternative animal models and existing clinical evidence suggests that a core/common feature may be early DA dysfunction. That this could originate from an early alteration in DA development is not a radical premise but the concept itself is extremely hard to assess in humans for a variety of obvious temporal and ethical reasons. However, understanding how the potential cascade of events after early alterations in DA neuron development influence other neurotransmitter systems in animal models, such as the DVD-deficient rat, may increase our understanding of the actual etiology of schizophrenia. Furthermore, subtle alterations to DA development may provide a platform to learn and understand the variable outcomes associated with a range of "second-hit" targets. The future of basic schizophrenia research should be focused on early dopaminergic development with the goal of further understanding existing and underlying abnormalities in schizophrenia patients that may, in turn, direct treatment solutions in the clinic.
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